Clinical Trials

46 enrolled

Small Cell Lung Carcinoma

NCT06623422 2026-04-14

INTerpath-009

680 enrolled

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Non-Small-Cell Lung

NCT06890338 2026-04-14

A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.

140 enrolled

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms

NCT07155174 2026-04-14

SEZanne

180 enrolled

Phase 3 Not yet recruiting

Small Cell Lung Carcinoma

NCT07502300 2026-04-14

A Study Comparing BL-B01D1 Combined With Tislelizumab Versus Platinum-containing Chemotherapy Combined With Tislelizumab as First-line Treatment in Patients With Extensive-stage Small Cell Lung Cancer

562 enrolled

Small Cell Lung Carcinoma

NCT02609776 2026-04-13

CHRYSALIS

751 enrolled 2 FDA

Carcinoma, Non-Small-Cell Lung

NCT03393884 2026-04-13

OVATION 2

130 enrolled

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms

NCT04077463 2026-04-13

Chrysalis-2

701 enrolled

Phase 3 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT04538664 2026-04-13

PAPILLON

308 enrolled 12 charts 2 FDA

Carcinoma, Non-Small-Cell Lung

NCT04686305 2026-04-13

DL03

Phase 1 Recruiting

304 enrolled

Carcinoma, Non-Small-Cell Lung

NCT05498428 2026-04-13

PALOMA-2

520 enrolled

Carcinoma, Non-Small-Cell Lung

NCT05595460 2026-04-13

Study of RYZ101 in Combination With SoC in Subjects With SSTR+ ES-SCLC

21 enrolled

SCLC,Extensive Stage

NCT05739981 2026-04-13

MRD

Phase 1/2 Recruiting

30 enrolled

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT06312137 2026-04-13

TroFuse-019

780 enrolled

Carcinoma, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT06333951 2026-04-13

Anvumetostat Alone or in Combination With Other Therapies in Subjects With Advanced Thoracic Tumors With Homozygous MTAP-deletion (Master Protocol) (MTAPESTRY 104).

Phase 1 Recruiting

500 enrolled

Carcinoma, Non-Small-Cell Lung, Neoplasms

NCT06385080 2026-04-13

OrigAMI-4

Phase 1/2 Recruiting

287 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT06448754 2026-04-13

eVOLVE-01

180 enrolled

Carcinoma, Non-Small-Cell Lung

NCT06743126 2026-04-13

SUPRAME

360 enrolled

Dermatologic

Melanoma, Cutaneous Malignant

NCT06793215 2026-04-13

Krascendo 2

600 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT06841354 2026-04-13

TroFuse-011

1,000 enrolled

Breast

Parkinson Disease 4, Autosomal Dominant Lewy Body, Triple Negative Breast Neoplasms

NCT06915025 2026-04-13

OVATION-3

500 enrolled

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT06952504 2026-04-13

TroFuse-033

1,123 enrolled

Parkinson Disease 4, Autosomal Dominant Lewy Body, Endometrial Neoplasms

NCT06966700 2026-04-13

A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)

2,400 enrolled

Breast

Parkinson Disease 4, Autosomal Dominant Lewy Body, Breast Neoplasms, Triple Negative Breast Neoplasms

NCT07190248 2026-04-13

KANDLELIT-007

675 enrolled

Carcinoma, Non-Small-Cell Lung

NCT07221474 2026-04-13

INTerpath-13

180 enrolled

Squamous Non-small Cell Lung Cancer

NCT07227597 2026-04-13

MK-6070-003

Phase 1/2 Recruiting

170 enrolled

Small Cell Lung Cancer Extensive Stage

NCT07252739 2026-04-13

KEYMAKER-U01 Substudy 01J: A Study of Pembrolizumab Plus MK-1084 in Participants With Non-Small Cell Lung Cancer (NSCLC) With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) G12C Mutations (MK-3475-01J/KEYMAKER-U01J)

130 enrolled

Parkinson Disease 4, Autosomal Dominant Lewy Body, Neoplasms

NCT07276399 2026-04-13

OrigAMI-5

Phase 3 Not yet recruiting

500 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT07524257 2026-04-13

ResQ1010-NSCLC: NAI + Chemoimmunotherapy vs Chemoimmunotherapy for First-Line Advanced/Metastatic NSCLC

494 enrolled

Carcinoma, Non-Small-Cell Lung

NCT07216703 2026-04-09

TroFuse-036

1,023 enrolled

Parkinson Disease 4, Autosomal Dominant Lewy Body, Uterine Cervical Neoplasms

NCT04083599 2026-04-08

GEN1042 Safety Trial and Anti-tumor Activity in Participants With Malignant Solid Tumors

DermatologicGastrointestinalHead & NeckThoracic

350 enrolled

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Melanoma, Colorectal Neoplasms

NCT04663347 2026-04-08

EPCORE™ NHL-2

543 enrolled

Lymphoid

Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse

NCT05083481 2026-04-08

A Study of ASP1570 Taken by Itself, or ASP1570 Taken Together With Either Pembrolizumab, Standard Therapies, or Both, in Adults With Solid Tumors

226 enrolled

Other solid neoplasm

Advanced Solid Tumors

NCT06057038 2026-04-08

A Safety Trial of GEN1042 in Japanese Subjects With Malignant Solid Tumors